JPH0475890B2 - - Google Patents
Info
- Publication number
- JPH0475890B2 JPH0475890B2 JP60164044A JP16404485A JPH0475890B2 JP H0475890 B2 JPH0475890 B2 JP H0475890B2 JP 60164044 A JP60164044 A JP 60164044A JP 16404485 A JP16404485 A JP 16404485A JP H0475890 B2 JPH0475890 B2 JP H0475890B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- cell differentiation
- weight
- promoting
- nerve cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002569 neuron Anatomy 0.000 claims description 35
- 230000024245 cell differentiation Effects 0.000 claims description 18
- 230000001737 promoting effect Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 244000273928 Zingiber officinale Species 0.000 description 4
- 235000006886 Zingiber officinale Nutrition 0.000 description 4
- 244000126002 Ziziphus vulgaris Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000008397 ginger Nutrition 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
- 244000000626 Daucus carota Species 0.000 description 3
- 235000002767 Daucus carota Nutrition 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000017803 cinnamon Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000008989 cinnamomi cortex Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は神経細胞分化促進剤に関するものであ
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a nerve cell differentiation promoting agent.
［従来の技術および問題点］
近年、人口の高齢化に伴い、老人性痴呆の患者
が増加しており、また脳血管障害による痴呆の患
者も増加している。[Prior Art and Problems] In recent years, with the aging of the population, the number of patients with senile dementia is increasing, and the number of patients with dementia due to cerebrovascular disorders is also increasing.
これらの痴呆に対する的確な予防法、治療法は
知られておらず、対症療法として、塩酸ニカルジ
ピン等の脳血管拡張剤やホパンテン酸カルシウム
等の脳代謝賦活剤が臨床応用されているが、治療
するための有効な治療薬は存在しなかった。 Accurate prevention and treatment methods for these dementias are not known, and cerebral vasodilators such as nicardipine hydrochloride and cerebral metabolism activators such as calcium hopanthenate have been clinically applied as symptomatic treatments. There were no effective treatments for this.
そこで本発明は、老人性痴呆に有効な神経細胞
分化促進剤を提供することを目的とする。 Therefore, an object of the present invention is to provide a nerve cell differentiation promoting agent effective for senile dementia.
［問題点を解決するための手段］
本発明者等は、種々の漢方処方について神経細
胞分化促進効果に関する研究を行つた結果、柴胡
（Bupleuri Radix）、芍薬（Paeoniae Radix）、
半夏（Pinelliae Tuber）、桂皮（Cinnamomi
Cortex）、大棗（Zizyphi Frectus）、黄〓
（Scutellariae Radix）、人参（Ginseng Radix）、
甘草（Glycyrrhizae Radix）、生姜（Zingiberis
Rhizoma）からなる漢方処方、すなわち小柴胡
湯合桂枝加芍薬湯に神経細胞分化促進効果のある
ことを見出だした。本発明はこの知見に基づくも
ので、小柴胡湯合桂枝加芍薬湯からなる神経細胞
分化促進剤を提供するものである。[Means for Solving the Problems] The present inventors conducted research on the effect of promoting nerve cell differentiation on various Chinese herbal prescriptions, and found that Bupleuri Radix, Paeoniae Radix, Paeoniae Radix,
Pinelliae Tuber, Cinnamomi
Cortex), large jujube (Zizyphi Frectus), yellow
(Scutellariae Radix), Ginseng (Ginseng Radix),
Licorice (Glycyrrhizae Radix), Ginger (Zingiberis)
We discovered that Shosaikoto Gokeishikashakuyakuto, a Chinese herbal formula consisting of Rhizoma), has the effect of promoting neuronal differentiation. The present invention is based on this knowledge and provides a neuron differentiation promoter comprising Shosaikoto Gokeishikashakuyakuto.
小柴胡湯合桂枝加芍薬湯は、漢方の成書（診療
医典）にその薬効が記載されており、てんかん、
夜尿症、潰瘍性大腸炎等の諸疾患に使用されてい
るが、神経細胞分化促進効果のあることは従来全
く知られていなかつたことである。 The medicinal effects of Shosaikoto Gokeishikashakuyakuto are listed in the Chinese herbal texts (Clinic Medical Encyclopedia), and are effective against epilepsy,
Although it has been used to treat various diseases such as nocturnal enuresis and ulcerative colitis, it was not previously known that it had the effect of promoting nerve cell differentiation.
［発明の作用効果］
本発明による神経細胞分化促進剤は、すぐれた
神経細胞分化促進作用を示す。従つて、本発明に
よれば、従来治療薬の存在しなかつた老人性痴
呆、脳血管障害性痴呆の分野において、画期的な
治療薬を提供するという重大な効果が得られる。
さらに、本発明による神経細胞分化促進剤はその
効果から、てんかん等の疾患に伴う精神遅滞もし
くは精神神経障害、パーキンソン氏病、自律神経
失調症、まはは神経細胞障害による各種疾患の治
療に用いることができ、脳外科手術後の回復促進
に用いることもできる。[Actions and Effects of the Invention] The agent for promoting nerve cell differentiation according to the present invention exhibits an excellent effect of promoting nerve cell differentiation. Therefore, the present invention has the significant effect of providing an epoch-making therapeutic agent in the fields of senile dementia and cerebrovascular disease dementia, for which no conventional therapeutic agent exists.
Further, due to its effects, the agent for promoting neuronal cell differentiation according to the present invention can be used to treat mental retardation or neuropsychiatric disorders associated with diseases such as epilepsy, Parkinson's disease, autonomic nervous disorder, or various diseases caused by neuronal cell disorders. It can also be used to promote recovery after brain surgery.
［実施例］
小柴胡湯合桂枝加芍薬湯は、柴胡７ｇ、芍薬６
ｇ、半夏５ｇ、桂皮４ｇ、大棗４ｇ、黄〓３ｇ、
人参３ｇ、甘草２ｇ、生姜１ｇを600mlの水で煎
じて350mlとし滓を取り去り、これを神経細胞分
化促進剤として３回に分けて服用することもでき
るが、服用のし易さ、携帯の便利さを考慮して漢
方薬エキス剤としたものを神経細胞分化促進剤と
して用いることもできる。たとえば、柴胡５〜８
重量部、芍薬４〜７重量部、半夏４〜５重量部、
桂皮３〜５重量部、大棗３〜５重量部、黄〓２〜
４重量部、人参２〜４重量部、甘草１〜３重量
部、生姜0.5〜２重量部を10倍量の水で熱時抽出
して得られた抽出液を過後、乾燥して神経細胞
分化促進剤である小柴胡湯合桂枝加芍薬湯エキス
粉末を得、これに通常の製剤に用いる適当な賦形
剤、補助剤等を加えて製剤製造の常法に従つて散
剤、顆粒剤、錠剤、カプセル剤などの製剤にする
ことができる。[Example] Shosaikoto Gokeishikashakuyakuto contains 7g of saiko and 6g of shakuyaku.
g, half summer 5g, cinnamon 4g, large jujube 4g, yellow 3g,
You can also decoct 3g of carrots, 2g of licorice, and 1g of ginger in 600ml of water, make 350ml, remove the dregs, and take this in three doses as a nerve cell differentiation promoter, but it is easy to take and convenient to carry. Taking this into consideration, a Chinese herbal medicine extract can also be used as a nerve cell differentiation promoter. For example, Saiko 5-8
parts by weight, 4 to 7 parts by weight of peonies, 4 to 5 parts by weight of Hanka,
3-5 parts by weight of cinnamon, 3-5 parts by weight of jujube, 2-2 parts by weight of yellow
4 parts by weight, 2 to 4 parts by weight of carrot, 1 to 3 parts by weight of licorice, and 0.5 to 2 parts by weight of ginger with 10 times the amount of water. Shosaikoto Gokeishikashakuyakuto extract powder, which is an accelerator, is obtained, and appropriate excipients, adjuvants, etc. used in ordinary formulations are added thereto, and powders, granules, tablets, etc. are prepared according to the conventional method for manufacturing formulations. It can be made into a preparation such as a capsule.
本発明の神経細胞分化促進剤の製造の具体例を
示すと次の如くである。 A specific example of the production of the nerve cell differentiation promoting agent of the present invention is as follows.
具体例
柴胡７ｇ、芍薬６ｇ、半夏５ｇ、桂皮４ｇ、大
棗４ｇ、黄〓３ｇ、人参３ｇ、甘草２ｇ、生姜１
ｇに10倍量すなわち350mlの水を加えて１時間、
100℃で加熱抽出し、得られた抽出液を過後、
スプレードライして、4.5ｇの乾燥エキス粉末を
得た。Specific examples: 7 g of saiko, 6 g of peonies, 5 g of half summer, 4 g of cinnamon, 4 g of jujube, 3 g of yellow, 3 g of carrot, 2 g of licorice, 1 g of ginger
Add 10 times the amount of water, i.e. 350ml, to g and boil for 1 hour.
After heating and extracting at 100℃ and filtering the resulting extract,
Spray drying yielded 4.5 g of dry extract powder.
［発明の効果］
本発明の神経細胞分化促進剤の神経細胞分化促
進作用について実験例を挙げて説明する。[Effects of the Invention] The action of the agent for promoting neuronal cell differentiation of the present invention in promoting neuronal cell differentiation will be explained by giving experimental examples.
実験例
マスウの妊娠18日目に胎仔を取り出し、その胎
仔の大脳皮質を無菌の状態で摘出して、100メツ
シユ（140μｍ）のふるいに通すことにより単一
の神経細胞を得た。この神経細胞を、20％仔牛血
清を含む培養液（日水MEM）に加え、１×106
細胞／mlの濃度に調製し、これを神経細胞液とし
て５mlずつシヤーレに入れた。また、具体例で得
られた本発明の神経細胞分化促進剤を200μｇ／
mlとなるように培養液に溶解し、0.2μｍのメンブ
ランフイルターを通して無菌とした後、上記神経
細胞液にそれぞれ５mlずつ添加した。これを培養
し、経時的に細胞を観察して、48時間後に顕微鏡
写真に記録した［第１Ａ図および第１Ｂ図、（写
真中、黒色楕円形の部分は神経細胞であり、神経
細胞から伸びている線上の部分が神経突起であ
る）］。尚、コントロールは、具体例で得られた本
発明の神経細胞分化促進剤を溶解させない以外は
上記と同様にして48時間後に顕微鏡写真に記録し
た（第２Ａ図および第２Ｂ図）。Experimental Example A mouse fetus was removed on the 18th day of pregnancy, and the cerebral cortex of the fetus was excised under aseptic conditions and passed through a 100 mesh (140 μm) sieve to obtain a single neuron. These neurons were added to a culture medium containing 20% calf serum (Nissui MEM), and 1×10 6
The concentration was adjusted to 5 cells/ml, and 5 ml of this was added to a shear dish as a nerve cell solution. In addition, 200 μg/g of the neuron differentiation promoter of the present invention obtained in the specific example was added.
The cells were dissolved in a culture medium to a volume of 1.0 ml, passed through a 0.2 μm membrane filter to make them sterile, and then added to each of the above nerve cell suspensions in an amount of 5 ml. This was cultured, and the cells were observed over time and recorded in micrographs after 48 hours [Figures 1A and 1B, (in the photographs, the black oval parts are nerve cells, and the cells extend from the nerve cells. The part on the line that is indicated by the line is the neurite)]. As a control, micrographs were taken after 48 hours in the same manner as above except that the nerve cell differentiation promoting agent of the present invention obtained in the specific example was not dissolved (FIGS. 2A and 2B).
その結果、コントロールに比べて神経細胞分化
促進剤を含有するものは、神経突起の長さの伸び
が著しいことから、本発明の神経細胞分化促進剤
は神経細胞に働いて神経突起を伸ばし、著明な分
化の促進作用を有することが確認された。 As a result, compared to the control, those containing the neuron differentiation promoter showed a remarkable increase in the length of neurites. It was confirmed that it has a clear differentiation promoting effect.
また、コントロールに比べて神経細胞分化促進
剤を含有するものは、明らかに細胞数が多いこと
より、神経細胞の脱落を防ぐメンテナンス作用を
有することも確認された。これらの作用は、脳に
おける神経細胞のみならず、脳以外の神経等に対
しても期待できる。 Furthermore, compared to the control, those containing a neuron differentiation promoter clearly had a higher number of cells, and it was also confirmed that they had a maintenance effect to prevent neuron shedding. These effects can be expected not only on nerve cells in the brain but also on nerves outside the brain.
次に、本発明の神経細胞分化促進剤の経口投与
での急性毒性試験をICR系雌雄マウス、および
SD系雌雄ラツトを用いて行つたところ、具体例
で得た本発明の神経細胞分化促進剤は、15ｇ／Kg
（投与限界）の経口投与でも死亡例はなかつた。
このように、本発明の神経細胞分化促進剤は、極
めて毒性が低く安全性の高いものである。本発明
における実験データおよび急性毒性試験の結果か
ら考えて、本発明の神経細胞分化促進剤の有効投
与量は、患者の年令、体重、疾患の程度によつて
も異なるが、通常成人量で乾燥エキス粉末量とし
て１日量３〜15ｇを症状に合わせて、１日３回に
分けての服用が適当と認められる。 Next, we conducted an acute toxicity test by oral administration of the agent for promoting neuronal cell differentiation of the present invention in male and female ICR mice, and
When carried out using SD male and female rats, the neuron differentiation promoter of the present invention obtained in the specific example was found to have a concentration of 15g/Kg.
There were no deaths even after oral administration (dose limit).
Thus, the neuron differentiation promoting agent of the present invention has extremely low toxicity and high safety. Considering the experimental data and acute toxicity test results of the present invention, the effective dose of the neuronal differentiation promoting agent of the present invention varies depending on the age, weight, and severity of the disease of the patient, but is usually an adult dose. It is considered appropriate to take the dry extract powder at a daily dose of 3 to 15 g divided into three times a day, depending on the symptoms.
次に、用例を示して、具体的に説明するが、本
発明は、これにより制限されるものではない。 Next, the present invention will be specifically explained using an example, but the present invention is not limited thereto.
用例 １
上記の具体例により製造した薬剤200ｇを乳糖
89ｇおよびステアリン酸マグネシウム１ｇと混合
し、この混合物を単発式打錠機にて打錠して、直
径20mm、重量約2.3ｇのスラツグ錠を作り、これ
をオシレーターにて粉砕し、整粒し、篩別して20
〜50メツシユの粒子の良好な顆粒剤を得た。Example 1 200g of the drug produced according to the above example was added to lactose.
89 g of magnesium stearate and 1 g of magnesium stearate, the mixture was compressed using a single-shot tablet machine to make slug tablets with a diameter of 20 mm and a weight of approximately 2.3 g, which were crushed using an oscillator and sized, 20 after sifting
Good granules of ~50 mesh particles were obtained.
この顆粒剤は、症状に合わせて１日量1.5〜7.0
ｇ（本発明の神経細胞分化促進剤の乾燥エキス粉
末重量として1.03〜4.83ｇに相当）を１日３回服
用する。 The daily dose of this granule is 1.5 to 7.0 depending on the symptoms.
g (equivalent to 1.03 to 4.83 g as dry extract powder weight of the nerve cell differentiation promoter of the present invention) three times a day.
用例 ２
上記の具体例により製造した薬剤200ｇを微結
晶セルロース20ｇよおびステアリン酸マグネシウ
ム５ｇと混合し、この混合物を単発式打錠機にて
打錠し直径７mm、重量225mgの錠剤を製造した。
本錠剤１錠中には本発明の神経細胞分化促進剤の
乾燥エキス粉末を200mg含有する。本錠剤は、症
状に合わせて１回量５〜20錠を１日３回服用す
る。Example 2 200 g of the drug produced according to the above specific example was mixed with 20 g of microcrystalline cellulose and 5 g of magnesium stearate, and this mixture was compressed using a single-shot tablet machine to produce tablets with a diameter of 7 mm and a weight of 225 mg.
One tablet of the present invention contains 200 mg of dry extract powder of the nerve cell differentiation promoter of the present invention. This tablet is taken in doses of 5 to 20 tablets three times a day, depending on the symptoms.
用例 ３
上記の具体例により製造した約500mgを硬カプ
セルに充填した。本カプセル剤は、症状に合わせ
て６〜30カプセルを１日３回に分けて服用する。Example 3 Approximately 500 mg of the product prepared according to the above example was filled into hard capsules. This capsule is to be taken in 6 to 30 capsules three times a day, depending on the symptoms.
第１Ａ図および第１Ｂ図は、本発明の神経細胞
分化促進剤を用いて48時間培養した神経細胞の顕
微鏡写真（200倍）であり、第２Ａ図および第２
Ｂ図は、本発明の神経細胞分化促進剤を用いずに
48時間培養した神経細胞の顕微鏡写真（200倍）
である。
Figures 1A and 1B are micrographs (200x magnification) of neurons cultured for 48 hours using the agent for promoting neuronal cell differentiation of the present invention, and Figures 2A and 2
Figure B shows the results obtained without using the neuronal differentiation promoting agent of the present invention.
Micrograph of neurons cultured for 48 hours (200x magnification)
It is.
Claims (1)
化促進剤。1. A nerve cell differentiation promoter consisting of Shosaikoto Gokeishikashakuyakuto.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60164044A JPS6226229A (en) | 1985-07-26 | 1985-07-26 | Nervous cell differentiation promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60164044A JPS6226229A (en) | 1985-07-26 | 1985-07-26 | Nervous cell differentiation promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6226229A JPS6226229A (en) | 1987-02-04 |
| JPH0475890B2 true JPH0475890B2 (en) | 1992-12-02 |
Family
ID=15785733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60164044A Granted JPS6226229A (en) | 1985-07-26 | 1985-07-26 | Nervous cell differentiation promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6226229A (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04275224A (en) * | 1991-03-02 | 1992-09-30 | Kissei Pharmaceut Co Ltd | Therapeutic agent for dementia |
| JP5054863B2 (en) | 1997-11-04 | 2012-10-24 | 帝國製薬株式会社 | Treatment for ulcerative colitis |
| KR100382564B1 (en) * | 1998-05-14 | 2003-07-16 | 김기영 | Herbal composition for prevention and treatment of alzheimer's disease |
| KR20000002473A (en) * | 1998-06-20 | 2000-01-15 | 신민규 | Medication for preventing and curing degenerative cerebral neural disease |
| WO2003006039A1 (en) * | 2001-07-11 | 2003-01-23 | Regen Biotech, Inc. | A composition for the protection and regeneration of nerve cells containing the extract of scutellaria radix |
| JP2006206584A (en) * | 2004-12-27 | 2006-08-10 | Tohoku Univ | AGGREGATION INHIBITOR OF beta-AMYLOID PROTEIN, DECOMPOSER FOR AGGREGATED beta-AMYLOID PROTEIN, ANTIDEMENTIAL AGENT AND ANTIDEMENTIAL FOOD |
| EP2987495A1 (en) * | 2007-10-25 | 2016-02-24 | Yale University | Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome |
| US20110171329A1 (en) * | 2009-07-24 | 2011-07-14 | Henrich Cheng | Method for treatment of neural injuries |
| CN103920112A (en) * | 2014-03-28 | 2014-07-16 | 徐明秀 | Traditional Chinese medicinal grains for treating parkinsonism and inspection method of traditional Chinese medicinal grains |
| CN105169155A (en) * | 2015-09-06 | 2015-12-23 | 崔红霞 | Traditional Chinese medicine for treating infantile enuresis |
-
1985
- 1985-07-26 JP JP60164044A patent/JPS6226229A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6226229A (en) | 1987-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3328262C2 (en) | ||
| JPS5936619A (en) | Carcinostatic adjuvant | |
| JPH0475890B2 (en) | ||
| CN107950929A (en) | It is a kind of that there is composition for improving sleep function and its preparation method and application | |
| CN102988905B (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN101032524B (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food | |
| JP2629251B2 (en) | Anti-dementia agent | |
| CN107375829A (en) | Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation | |
| CN113713048A (en) | Solid rhizoma gastrodiae refreshment traditional Chinese medicine composition and preparation method and application thereof | |
| CN102824548A (en) | Traditional Chinese medicine composition for treating asthenopia and preparation method thereof | |
| CN106360716A (en) | Traditional Chinese medicinal composition for improving body immunity and sleep, and preparation method thereof | |
| CN1129118A (en) | Compounded preparation of notoginseng | |
| CN104721528A (en) | Traditional Chinese medicine composition for nourishing yin and blood, tonifying heart and soothing nerves and preparation method thereof | |
| CN115105571B (en) | Traditional Chinese medicine compound composition for treating ischemic stroke and preparation method thereof | |
| CN112426454B (en) | Traditional Chinese medicine compound composition with anti-anxiety effect and preparation method and application thereof | |
| CN112076276B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN102688308B (en) | Traditional Chinese medicine composition for ischemic stroke treatment as well as preparation method and application thereof | |
| CN107126508A (en) | A kind of pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN1064844C (en) | Chinese medicine | |
| CN105030948A (en) | Drug combination and new application of preparation thereof | |
| CN105963558A (en) | Plant extract for treating fever of children and application thereof | |
| CN112891463A (en) | Oral medicine for treating apoplexy |